Table 4.
Clinical and molecular features for each genomic group
| Variable | 1p/19q Codeletion | 19q Loss | 11p Loss | 7 Gain | 19q Gain | Un classified | P value* |
|---|---|---|---|---|---|---|---|
| n = 126 (%) | 32 | 17 | 9 | 17 | 7 | 44 | |
| Type (O/M/A) (%) | 78/16/6 | 29/70/0 | 22/22/56 | 48/29/23 | 29/29/42 | 25/54/21 | .00001* |
| Age, median (years) | 42 | 35 | 43 | 40 | 41 | 33 | .02 |
| Sex (M/F) | 0.8 | 1.4 | 2 | 1.4 | 6 | 0.9 | NS |
| KPS, median (%) | 90 | 90 | 90 | 90 | 90 | 90 | NS |
| Resection/Biopsy (%) | 75/25 | 65/35 | 77/21 | 65/35 | 75/25 | 77/23 | NS |
| OS, years median (years) | 12.1 | 3.5 | 5.2 | 3.9 | 8.4 | 5.3 | .0002* |
| PFS, years median (years) | 6.6 | 2.2 | 2.7 | 2.2 | 3 | 3.5 | .02 |
| IDH mutation (%) | 100 | 75 | 89 | 77 | 83 | 90 | NS |
| p53 overexpression (%) | 13 | 47 | 35 | 19 | 33 | 37 | .0001* |
| MGMT promoter methylation (%) | 87 | 69 | 100 | 50 | 83 | 75 | .06 |
*Significant at P <.05.
Abbreviations: F, female; KPS, Karnofsky Performance Status;M, male; NS, not significant; O/M/A, oligodendroglioma/oligoastrocytoma or mixed/astrocytoma; OS, overall survival; PFS, progression-free survival